Progress of Neutralizing Antibodies Against SARS-CoV-2

doi:10.14009/j.issn.1672-2124.2022.11.027

您当前的位置：

首页 >

文章列表页 >

Progress of Neutralizing Antibodies Against SARS-CoV-2

更新时间：2023-04-16

- Progress of Neutralizing Antibodies Against SARS-CoV-2
- Issue 11, Pages: 1400-1403(2022)
- 作者机构：
  
  北京医院药学部国家老年医学中心中国医学科学院老年医学研究院北京市药物临床风险与个体化应用评价重点实验室(北京医院)
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.11.027
  CLC： R978.7
- Published：2022，
扫描看全文
Progress of Neutralizing Antibodies Against SARS-CoV-2. [J]. (11):1400-1403(2022)
DOI：

Progress of Neutralizing Antibodies Against SARS-CoV-2. [J]. (11):1400-1403(2022) DOI： 10.14009/j.issn.1672-2124.2022.11.027.

摘要

新型冠状病毒肺炎疫情在全球范围的持续发展促使人们开展针对该疾病的深入研究，包括治疗药物的研究。中和抗体药物作为一种很有前景的特异性抗病毒药已成功应用于部分病毒感染性疾病的治疗。目前，国际上针对新型冠状病毒（SARS-CoV-2）中和抗体的研发进展十分迅速，已有多个抗体药物获得紧急使用授权。本文主要通过SARS-CoV-2中和抗体的作用靶点、药物研究进展以及需要关注的问题与不足等方面进行综述。

Abstract

The ongoing global development of the COVID-19 epidemic has led to in-depth research on the disease

including therapeutic agents. As a promising specific antiviral agents

the neutralizing antibodies have been successfully applied on some viral infectious diseases. Currently

the development of neutralizing antibodies against SARS-CoV-2 is progressing rapidly internationally

several antibodies have been authorized for emergency use. This paper reviews the effect targets of neutralizing antibodies against SARS-CoV-2

the research progress of drugs

and the problems and shortcomings that need attention.

关键词

新型冠状病毒中和抗体研究进展临床试验

Keywords

SARS-CoV-2Neutralizing antibodyResearch progressClinical trials

references

查看原文

Views

566

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress of Neurotoxicity Induced by Irrational Use of Sophorae tonkinensis Radix et Rhizoma

Progress of Traditional Chinese Medicine in Promoting Wound Healing After Anal Fistula Surgery

Recommendations and Evidence for COVID-19 Vaccine in Patients with Atopic Dermatitis

Progress of Traditional Chinese Medicine Injections and Extracts in the Treatment of Sepsis-Induced Acute Lung Injury

Recommendations and Evidence for COVID-19 Vaccine in Patients with Systemic Lupus Erythematosus

Related Author

CAO Junling

HE Ting

MAO Liuying

MA Lina

ZHANG Yanli

LIU Tiantian

PEI Yan

WU Qiong

Related Institution

Dept. of Pharmacy, Dongfang Hospital, Beijing University of Chinese Medicine

Dept.of Anus and Intestine, the First Affiliated Hospital of Hebei University of Chinese Medicine

Graduate School, Hebei University of Chinese Medicine

Dept.of Dermatology, Chengdu Second People’s Hospital

Dept.of Neurology, Sichuan Academy of Medical Sciences ＆ Sichuan Provincial People’s Hospital

⁰